HDAC inhibition potentiates immunotherapy in triple negative breast cancer

@inproceedings{TerranovaBarberio2017HDACIP,
  title={HDAC inhibition potentiates immunotherapy in triple negative breast cancer},
  author={Manuela Terranova-Barberio and Scott E Thomas and Niwa Ali and Nela Pawlowska and Jeenah Park and Gregor Krings and Michael D Rosenblum and Alfredo Budillon and Pamela N. Munster},
  booktitle={Oncotarget},
  year={2017}
}
Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various types of cancer, including breast cancer. Here, we investigated a new combination strategy where histone deacetylase inhibitors (HDACi) are applied with immune checkpoint inhibitors to improve immunotherapy responses in TNBC. Testing different… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS